Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

However, there was a borderline significant 2-fold increased risk for recurrence among the patients with ER+ tumors who ever received any type of endocrine treatment and had IGF1R strong tumor expression compared with IGF1R not strong tumor expression, HR adj (2.07; 95% CI 0.98-4.37) adjusted for prognostic markers and treatment with chemotherapy and radiotherapy.

also in 11,409 other papers